TAF1 SPLICING VARIANTS AND PROLYL HYDROXYLASE INHIBITORS IN HUNTINGTON’S DISEASE

TAF1 SPLICING VARIANTS AND PROLYL HYDROXYLASE INHIBITORS IN HUNTINGTON’S DISEASE

Bibliographic Details
Main Authors:	Claudia Rodríguez-López, Ivó Hernández Hernández, María González-Bermejo, Marcos Casado Barbero, José Lucas
Format:	Article
Language:	English
Published:	Elsevier 2023-10-01
Series:	IBRO Neuroscience Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2667242123010138

Similar Items

Prolyl hydroxylases and therapeutics.
by: Smith, T, et al.
Published: (2010)

2-oxoglutarate analogue inhibitors of HIF prolyl hydroxylase.
by: Mole, D, et al.
Published: (2003)

Analogues of dealanylalahopcin are inhibitors of human HIF prolyl hydroxylases.
by: Schlemminger, I, et al.
Published: (2003)

Substrate selectivity of prolyl hydroxylases
by: McDonough, M
Published: (2018)

Regulation of HIF: prolyl hydroxylases.
by: Stolze, I, et al.
Published: (2006)

2-Oxoglutarate analogue inhibitors of prolyl hydroxylase domain 2.
by: Mecinović, J, et al.
Published: (2009)

Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors and Iron Metabolism
by: Chie Ogawa, et al.
Published: (2023-02-01)

Prolyl-hydroxylase inhibitors reconstitute tumor blood vessels in mice
by: Shunji Nishide, et al.
Published: (2020-06-01)

Structural and mechanistic studies on prolyl hydroxylases
by: Chowdhury, R
Published: (2008)

Inhibition of a viral prolyl hydroxylase
by: Langley, G, et al.
Published: (2019)

Molecular and Cellular Mechanisms of HIF Prolyl Hydroxylase inhibitors in Clinical Trials
by: Yeh, TL, et al.
Published: (2017)

Studies on spiro[4.5]decanone prolyl hydroxylase domain inhibitors
by: Holt-Martyn, J, et al.
Published: (2019)

Bibliometric analysis of hypoxia inducible factor prolyl hydroxylase inhibitor in anemia
by: Li Zheng, et al.
Published: (2022-09-01)

Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state
by: Amit A. Joharapurkar, et al.
Published: (2022-01-01)

HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons
by: Andrey A. Poloznikov, et al.
Published: (2021-01-01)

Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase, and is sensitive to off target inhibition by prolyl hydroxylase domain inhibitors that stabilise Hypoxia Inducible Factor
by: Kiriakidis, S, et al.
Published: (2017)

Impact of HIF prolyl hydroxylase inhibitors in heart failure patients with renal anemia
by: Takahiro Kambara, et al.
Published: (2024-03-01)

HIF-α Prolyl Hydroxylase Inhibitors and Their Implications for Biomedicine: A Comprehensive Review
by: Kiichi Hirota
Published: (2021-04-01)

Novel and selective small molecule inhibitors and activators for the prolyl hydroxylase domain enzyme
by: Holt-Martyn, J
Published: (2018)

Updates on Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in the Treatment of Renal Anemia
by: Jing Li, et al.
Published: (2022-10-01)

Iron homeostasis and its interaction with prolyl hydroxylases.
by: Mole, D
Published: (2010)

Structural, functional and evolutionary studies on prolyl-hydroxylases
by: Scotti, J
Published: (2014)

Selective inhibitors of a human prolyl hydroxylase (OGFOD1) involved in ribosomal decoding
by: Thinnes, C, et al.
Published: (2018)

Structure–Activity Relationships and Transcriptomic Analysis of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors
by: Andrey A. Poloznikov, et al.
Published: (2022-01-01)

Pleotropic effects of hypoxia-inducible factor-prolyl hydroxylase domain inhibitors: are they clinically relevant?
by: Yu-Hsiang Chou, et al.
Published: (2023-01-01)

Recent Advances in Developing Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylases and Their Therapeutic Implications
by: So Yeon Kim, et al.
Published: (2015-11-01)

Clinical Potential of Hypoxia Inducible Factors Prolyl Hydroxylase Inhibitors in Treating Nonanemic Diseases
by: Mengqiu Miao, et al.
Published: (2022-02-01)

Structural basis of prolyl hydroxylase domain inhibition by Molidustat
by: Figg, WD, et al.
Published: (2021)

The use of dioxygen by HIF prolyl hydroxylase (PHD1).
by: McNeill, L, et al.
Published: (2002)

Exploring the substrate selectivity of oxygen sensing prolyl hydroxylases
by: Lippl, K, et al.
Published: (2015)

Mass spectrometric studies on an oxygen sensing prolyl hydroxylase
by: Mecinovic, J, et al.
Published: (2007)

Determination and comparison of specific activity of the HIF-prolyl hydroxylases.
by: Tuckerman, JR, et al.
Published: (2004)

Collagen Prolyl 4-Hydroxylase as a Therapeutic Target
by: Vasta, James D., et al.
Published: (2020)

Collagen Prolyl Hydroxylases Are Bifunctional Growth Regulators in Melanoma
by: Atkinson, Aithne, et al.
Published: (2020)

Mechanistic studies on human prolyl hydroxylase domain 2
by: Fiorini, G
Published: (2024)

Role of prolyl hydroxylase domain proteins in bone metabolism
by: David Wolf, et al.
Published: (2022-03-01)

Structure–activity relationship and crystallographic studies on 4-hydroxypyrimidine HIF prolyl hydroxylase domain inhibitors
by: Holt-Martyn, JP, et al.
Published: (2019)

Dual-action inhibitors of HIF prolyl hydroxylases that induce binding of a second iron ion.
by: Yeoh, K, et al.
Published: (2013)

A fluorescent benzo[g]isoquinoline-based HIF prolyl hydroxylase inhibitor for cellular imaging
by: Mayer, M, et al.
Published: (2018)

Efficacy of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Clinical Parameters in Patients with Heart Failure
by: Mayu Yazaki, et al.
Published: (2024-01-01)